Clinical trial
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in…
NCT00085462 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00085462 |
|---|---|
| Title | Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, filgrastim, gp100-fowlpox vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate |
| Enrollment | 61 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Jun 11, 2004 |
| Last update posted | Jun 22, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: